@AmarPut @kamleshkhunti @EASDelearning @EASDnews @DanielJDrucker @AbdTahrani @escardio @mvaduganathan @DSNforumUK @GoggleDocs @radcliffeCARDIO @AskDrShashank @drkevinfernando Incomplete receptor blockage and ex9-39 compensatory mechanisms: https://t.co/os
In a randomised, double-blinded, placebo-controlled, crossover study, Lærke S. Gasbjerg, Filip K. Knop and colleagues show that GIP(3-30)NH2 is an efficacious GIP receptor antagonist applicable in human studies https://t.co/uhx1rI4h8B #pharmacology #incret
RT @DiabetologiaJnl: In a randomised, double-blinded, placebo-controlled, crossover study, Lærke S. Gasbjerg, Filip K. Knop and colleagues…
RT @DiabetologiaJnl: In a randomised, double-blinded, placebo-controlled, crossover study, Lærke S. Gasbjerg, Filip K. Knop and colleagues…
In a randomised, double-blinded, placebo-controlled, crossover study, Lærke S. Gasbjerg, Filip K. Knop and colleagues show that GIP(3-30)NH2 is an efficacious GIP receptor antagonist applicable in human studies https://t.co/uhx1rI4h8B #pharmacology #incret
RT @DiabetologiaJnl: In a randomised, double-blinded, placebo-controlled, crossover study, Lærke S. Gasbjerg, Filip K. Knop and colleagues…
RT @DanielJDrucker: Important study, look forward to greater understanding of endogenous GIP action in humans in studies using GIP(3-30)NH2…
RT @DiabetologiaJnl: In a randomised, double-blinded, placebo-controlled, crossover study, Lærke S. Gasbjerg, Filip K. Knop and colleagues…
Important study, look forward to greater understanding of endogenous GIP action in humans in studies using GIP(3-30)NH2 @DiabetologiaJnl https://t.co/nDoLh7tjte
In a randomised, double-blinded, placebo-controlled, crossover study, Lærke S. Gasbjerg, Filip K. Knop and colleagues show that GIP(3-30)NH2 is an efficacious GIP receptor antagonist applicable in human studies https://t.co/uhx1rIlS09 #pharmacology #incret
RT @DanielJDrucker: Emerging utility of the GIP(3-30) antagonist in humans. Looking forward to GIP(3-30) alone + OGTT @DiabetologiaJnl http…
RT @DanielJDrucker: Emerging utility of the GIP(3-30) antagonist in humans. Looking forward to GIP(3-30) alone + OGTT @DiabetologiaJnl http…
RT @DanielJDrucker: Emerging utility of the GIP(3-30) antagonist in humans. Looking forward to GIP(3-30) alone + OGTT @DiabetologiaJnl http…
Emerging utility of the GIP(3-30) antagonist in humans. Looking forward to GIP(3-30) alone + OGTT @DiabetologiaJnl https://t.co/SoT1eeq8It